Astrazeneca (AZN) Operating Expenses (2009 - 2026)

Astrazeneca (AZN) has reported Operating Expenses for 18 consecutive years, with -$8.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 9.95% year-over-year to -$8.4 billion; the TTM figure through Mar 2026 stood at -$34.9 billion (down 2.93% YoY), while the FY2025 annual figure was $34.2 billion, up 1.8% from the prior year.
• Operating Expenses came in at -$8.4 billion for Q1 2026 at Astrazeneca, up from -$9.4 billion in the prior quarter.
• The five-year high for Operating Expenses was -$6.7 billion in Q1 2023, with the low at -$10.1 billion in Q4 2024.
• Average Operating Expenses over 5 years is -$7.9 billion, with a median of -$7.7 billion recorded in 2023.
• The largest YoY upside for Operating Expenses was 12.53% in 2022 against a maximum downside of 90.12% in 2022.
• Year by year, Operating Expenses stood at -$7.2 billion in 2022, then retreated by 16.53% to -$8.4 billion in 2023, then dropped by 19.46% to -$10.1 billion in 2024, then climbed by 7.27% to -$9.4 billion in 2025, then grew by 10.07% to -$8.4 billion in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered -$8.4 billion, -$9.4 billion, and -$8.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.